EXHIBIT 99.2


1.   PRESS RELEASE


Contacts:     Thomas D. Weldon                    Gerard van Hamel Platerink
              Chairman                            Director, Investor Relations
              (770) 717 0904                      (770) 689 2735


                NOVOSTE CORPORATION ANNOUNCES THE APPOINTMENT OF
            ALFRED J. NOVAK AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Norcross,  Ga.,  October  16,  2002 - Novoste  Corporation  (NASDAQ:NOVT)  today
announced the  appointment  of Alfred J. Novak as President and Chief  Executive
Officer (CEO). Mr. Novak will also join the Board of Directors effective October
16, 2002, replacing William A. Hawkins.  Thomas D. Weldon,  current Chairman and
CEO, will remain Chairman of the Board of Directors.

Mr. Novak joins Novoste with wide-ranging  experience in the medical  technology
market,  including 12 years at Cordis Corporation,  a Johnson & Johnson company.
Al is currently Chairman of the Board of two medical technology companies: Orbus
Medical Technologies,  Inc., a stent technology company, and Transurgical, Inc.,
which  is  focused  on  treating  atrial   fibrillation   using  high  intensity
ultrasound.  Mr.  Novak is also a  Founding  Member of  Syntheon  LLC, a company
focused  on   minimally   invasive   medical   devices  for  the   vascular  and
gastroenterology markets.

Between 1996 and 1998, Mr. Novak served as President and CEO of Biosense,  Inc.,
which  developed a technology  that enables  physicians to accurately and safely
navigate  medical  instruments  within patients' bodies during a wide variety of
minimally invasive medical procedures. Biosense was sold to Johnson & Johnson in
October, 1997.

From 1984 to 1996 Mr. Novak worked at Cordis,  the  diversified  medical  device
company.  Between  1989 and 1996,  he served as the  company's  Chief  Financial
Officer and was a member of the group's executive committee. He helped to manage
the  company's  negotiated  sale to Johnson & Johnson in February  1996 for $1.8
billion  and  managed  the  integration  of  Cordis  with  Johnson  &  Johnson's
Interventional  Systems  business unit  resulting in an operation  with combined
revenues of $1.3 billion. Mr. Novak's other  responsibilities at Cordis included
VP of Marketing  and Sales  (Americas  Division),  Head of  Strategic  Planning,
Strategic Acquisitions,  Human Resources,  Corporate Development and Information
Systems.




Mr. Novak has an MBA from the Wharton School at the  University of  Pennsylvania
and earned his B.S. at the U.S. Merchant Marine Academy.

"I am extremely pleased that Al has joined the Novoste team",  Thomas D. Weldon,
Chairman,  commented.  "He has a first class track record in the medical  device
industry and will be a significant  addition to our  management  team. His broad
experience in managing public and private  companies,  business  development and
new  product  launches  are all highly  relevant to Novoste  today,  and we look
forward to his  leadership  in the years ahead.  This  concludes  the  executive
search process we commenced in February,  and I firmly believe we have found the
best candidate to serve Novoste's interests and help build shareholder value."

Mr. Novak added, "I am extremely pleased to join Novoste at this pivotal time in
the company's  and the  industry's  history.  I am confident I can help build on
Novoste's  impressive  achievements to date and add value for  shareholders  and
employees in the years ahead. I look forward to working with Tom, the management
team and my new colleagues at Novoste."

Mr.  Weldon  also  said,  "I would like to take this  opportunity  to thank Bill
Hawkins for his many  contributions to Novoste as Member of the Board. The Board
and the company as a whole join me in wishing him all the best for the future."


ABOUT NOVOSTE CORPORATION:
Novoste  Corporation,  based in Atlanta GA, develops advanced medical treatments
for  coronary  and vascular  diseases  and is the  worldwide  leader in vascular
brachytherapy.  The Company's  Beta-Cath(TM) System is commercially available in
the United States, as well as in the European Union and several other countries.
Novoste  Corporation shares are traded on the NASDAQ National Stock Market under
the symbol NOVT. For general company information,  please call (770) 717-0904 or
visit the Company's web site at www.novoste.com.

Statements  made in this press release that look forward in time or that express
management's beliefs, expectations or estimates regarding future occurrences are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform Act of 1995.  Actual results may differ materially from those
projected in these forward-looking statements based upon known and unknown risks
and  uncertainties,  including  continued market acceptance of the Beta-Cath(TM)
System,  continued demonstration of safety,  efficacy, and device performance in
post-market  surveillance studies,  competition and technological changes. These
and  other  risks  are  detailed  in  documents  filed by  Novoste  with the SEC
including  its Form 10-K for the year ended  December 31, 2001 and its Form 10-Q
for the quarter ended June 30, 2002.

                                      # # #


1543914v1